country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Art. -Nr.: HY-145557

Copy Link Print Information

Bezuclastinib

Name: Bezuclastinib
Brand: MedChemExpress
SKU: HY-145557
Price: 220.00 USD
Availability: InStock
Rating: 5 (1 reviews)

(Synonyms: CGT9486; PLX 9486)

1 Cited Publications

Kundenbewertung

Based on 1 publication(s) in Google Scholar

Bezuclastinib (CGT9486) is an orally active, highly selective tyrosine kinase inhibitor with potent activity against KIT D816V. Bezuclastinib can be used for the research of nonadvanced systemic mastocytosis (NonAdvSM).

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 98.81%
CAS. Nr.: 1616385-51-3
Formel: C₁₉H₁₇N₅O
Molecular Weight:331.37

Speicherung:

4°C, sealed storage, away from moisture and light

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

Bezuclastinib Chemical Structure

CAS. Nr.: 1616385-51-3

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- In Vivo
- Clinical Trial
Chemical Information
Publications (1)
Lösungsmittel & Löslichkeit
- In Vitro
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target^[1]

c-Kit

<1 μM (IC₅₀)

c-kit D816V

<1 μM (IC₅₀)

In Vivo

Bezuclastinib (25 mg/kg, p.o., 3 days) shows a brain:plasma ratio of 0.07 in rats^[2].

Pharmacokinetic Analysis in Rats^[2]

Route	Dose (mg/kg)	t_1/2 (h)	C_max (ng/mL)	AUC_last (h*ng/mL)
p.o.	25	2.8	2592±364	21509±2558

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS. Nr. 1616385-51-3
Appearance Solid
Molecular Weight 331.37
Formel C₁₉H₁₇N₅O
Color White to off-white
SMILES

O=C(C1=NNC(C)=C1C)NC2=CN=C3NC(C4=CC=CC=C4)=CC3=C2
Synonyms

CGT9486; PLX 9486
Versand

Room temperature in continental US; may vary elsewhere.
Speicherung

4°C, sealed storage, away from moisture and light

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

Publications (1)

All

Sort by:

Journal Impact Factor

bioRxiv

2026 Mar 25.

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 80 mg/mL (241.42 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

3.0178 mL

15.0889 mL

30.1777 mL

5 mM

0.6036 mL

3.0178 mL

6.0355 mL

10 mM

0.3018 mL

1.5089 mL

3.0178 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (272 KB)
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Guarnieri A, et al. Preclinical Data with KIT D816V Inhibitor Bezuclastinib (CGT9486) Demonstrates High Selectivity and Minimal Brain Penetrance. Blood. 2021, 138: 4595.

[2]. Guarnieri A, et al. Preclinical data identifies bezuclastinib as a differentiated KIT inhibitor with unique selectivity to KIT D816V and minimal evidence of brain penetration. MOLECULAR CANCER THERAPEUTICS. 2021, 20(12).

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	3.0178 mL	15.0889 mL	30.1777 mL	75.4444 mL
	5 mM	0.6036 mL	3.0178 mL	6.0355 mL	15.0889 mL
	10 mM	0.3018 mL	1.5089 mL	3.0178 mL	7.5444 mL
	15 mM	0.2012 mL	1.0059 mL	2.0118 mL	5.0296 mL
	20 mM	0.1509 mL	0.7544 mL	1.5089 mL	3.7722 mL
	25 mM	0.1207 mL	0.6036 mL	1.2071 mL	3.0178 mL
	30 mM	0.1006 mL	0.5030 mL	1.0059 mL	2.5148 mL
	40 mM	0.0754 mL	0.3772 mL	0.7544 mL	1.8861 mL
	50 mM	0.0604 mL	0.3018 mL	0.6036 mL	1.5089 mL
	60 mM	0.0503 mL	0.2515 mL	0.5030 mL	1.2574 mL
	80 mM	0.0377 mL	0.1886 mL	0.3772 mL	0.9431 mL
	100 mM	0.0302 mL	0.1509 mL	0.3018 mL	0.7544 mL

Bioz

Keywords

Bezuclastinib

1 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

MOQ

Minimum order quantity

100 mg

Angebot einholen Auf Lager

Other size

Angebot einholen

Amount: USD 0.00

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- In Vivo
- Clinical Trial
Chemical Information
Publications (1)
Lösungsmittel & Löslichkeit
- In Vitro
Reinheit & Dokumentation
Verweise

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Bezuclastinib

Elenestinib

Avapritinib

Imatinib

Velzatinib

c-Kit-IN-1

Ripretinib

Sunitinib

ISCK03

2-Deoxy-D-glucose

Regorafenib

AZD3229

Motesanib

Publications Citing Use of MedChemExpress (MCE) Bezuclastinib

Biologische Aktivität

Chemical Information

Publications (1)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Bioz

Bezuclastinib

Elenestinib

Avapritinib

Imatinib

Velzatinib

c-Kit-IN-1

Ripretinib

Sunitinib

ISCK03

2-Deoxy-D-glucose

Regorafenib

AZD3229

Motesanib

Publications Citing Use of MedChemExpress (MCE) Bezuclastinib

Biologische Aktivität

Chemical Information

Publications (1)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Bezuclastinib Related Classifications

HY-145557 Related Classifications

Bioz